COPD FOundation Research Innovation Update

The COPD Foundation is committed to accelerating the development and dissemination of innovative and appropriate treatment strategies for a broad spectrum of respiratory diseases, particularly COPD, non-CF bronchiectasis and nontuberculous mycobacterial (NTM) lung disease.

The Research Innovation Update (RIU) aims to highlight exciting innovations with the potential to impact treatments for individuals with respiratory conditions.


These are short videos that provide education around exciting innovations and progress in the COPD space.

Content for these videos will be created as part of a collaborative process for the Foundation and will feature academic and clinical experts, startups, and Corporate Partners.

Research Innovation Updates will be integrated into this COPD Foundation website similar to the library of educational videos that are currently available on our site: COPD Inhaler Educational Video Series and shared within our social media and professional educational activity channels including LinkedIn and The PRAXIS Nexus.

For Information about this program please contact Elisha Malanga, Chief Research Officer at riu@copdfoundation.org.


Redefining COPD: Lessons from COPDGene®

Redefining COPD: Lessons from COPDGene®

The COPDGene® Study is one of the largest studies ever to investigate the underlying genetic factors of Chronic Obstructive Pulmonary Disease (COPD) and to improve the understanding of how the disease may differ from person to person. Analysis of data from nearly 9,000 participants in the study revealed that a substantial portion of smokers with respiratory symptoms and imaging abnormalities do not manifest spirometric obstruction that, thus far, has been used to define COPD. (Lowe KE, Regan EA, Anzueto A, et al. COPDGene 2019: redefining the diagnosis of chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis. 2019; 6(5): 384-399. doi: https://dx.doi.org/10.15326/jcopdf.6.5.2019.0149).

These expanded criteria offer the potential to inform future interventions that could slow or halt disease progression in patients before disability or irreversible lung structural changes develop. Barry Make, MD, from National Jewish Hospital, Denver, Colorado explains these key findings and how to apply this information in current clinical practice.